FMFrank McCaughan

Frank McCaughan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Frank McCaughan has a total of 150 co-authors. Here are the top co-authors by number of shared publications:

  • Wenrui Guo

    The Victor Phillip Dahdaleh Heart & Lung Research Institute, Department of Medicine, University of Cambridge, Cambridge, UK

    7 shared publications
  • Namshik Han

    Milner Therapeutics Institute, University of Cambridge, Cambridge, United Kingdom

    4 shared publications
  • Rebecca Harris

    Milner Therapeutics Institute, University of Cambridge, Cambridge, UK

    4 shared publications
  • Linsey M Porter

    Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge, UK

    3 shared publications
  • Méabh MacMahon

    Milner Therapeutics Institute, University of Cambridge, Cambridge, UK

    3 shared publications
  • Paul J Lehner

    Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK

    3 shared publications

Latest Publications

  • Open Access

    Carcinogen-induced preinvasive human squamous lung cancer is characterised by a novel atypical basal cell state and presents opportunities for chemoprevention

    by Wenrui Guo, Holly A. R. Giles, Alice Chernaik, Yasin Memari, Joanna Xie, Daniella Black, Anne Hilgendorff, Christina Gabriel, Onder Yildirim, Helen Davies, et al.

    There are no adequate carcinogen-induced models of the earliest stages of human squamous lung cancer (LUSC), limiting the development of effective chemoprevention strategies. We developed a novel human model of early LUSC by exposing differentiated primary human airway cells to a chemical carcinogen known to cause murine LUSC. Carcinogen exposure induced a phenotype recapitulating the earliest stages of human LUSC and associated with the emergence of a novel population of atypical basal cells (ABCs). ABCs express key cancer hallmark markers but without evidence of either common LUSC-associated mutations or an emergent major clonal/subclonal population. We established the clinical relevance of this model by demonstrating enrichment of the ABC expression profile in independent clinical precancer specimens. We then show that capivasertib, a clinically approved kinase inhibitor, prevented the emergence of the abnormal phenotype and the accumulation of cells with an active DNA damage response. Further, capivasertib reversed the established phenotype; and remained effective when nebulised in vitro , mimicking therapeutic inhalation. Together, these findings establish a tractable human model of carcinogen-induced early LUSC and provide a proof-of-principle for repurposing targeted therapies for the prevention of lung cancer.

  • Open Access

    A scalable deep-learning framework for cancer detection using cell-free DNA shallow whole-genome sequencing

    by Haichao Wang, Paulius D. Mennea, Grainne McAndrew, Ozge Sonmezler, Dmitry S. Shcherbo, Emma-Jane Ditter, Sarah Østrup Jensen, Alessandra I. G. Buma, Christopher G. Smith, Zhao Cheng, et al.

    Cell-free DNA (cfDNA) in body fluids enables noninvasive cancer detection. Multifeature artificial intelligence (AI) can improve sensitivity by integrating diverse biomarkers when cancer signals are sparse. Tumor-informed assays that rely on mutations have limited practicality for early cancer detection. Emerging fragmentomic and epigenetic features underpin tumor-naive approaches to screening for individuals with low tumor burden. Here, we designed UNITE—a universal cfDNA feature ensemble framework that provides scalable cancer detection methods based on “genomic bin–fragment length” matrices derived from shallow whole-genome sequencing (sWGS) data at 0.1× depth. Using sWGS data from 2063 plasma samples (631 controls and 1432 cases from 26 cancer types), we systematically evaluated both XGBoost (UNITE-XGB) and convolutional neural networks (UNITE-CNN) across multiple feature spaces and cancer stages. In stage I-II cancer, UNITE-XGB and UNITE-CNN achieved 31 and 21% sensitivity, respectively, at 95% specificity. These findings provide roadmaps for developing multifeature AI beyond plasma biopsies.


  • Open Access

    A perspective towards building scalable, integrated, multicellular in vitro airway models with inverted airway-on-a-tube

    by Jack F. Murphy, Corrado Mazzaglia, Alice Chernaik, Frank McCaughan, Yan Yan Shery Huang

    摘要: 气道是人体呼吸系统的关键组成部分, 其结构和功能都非常复杂。 它由多种类型的上皮细胞组成, 这些细胞与血管内皮细胞共同协作, 构成了气道与血液之间的屏障。 此外, 气道还包含多种起支撑与调控作用的间质细胞, 这些细胞存在于细胞外基质 (ECM) 形成的三维环境中。 尽管呼吸系统疾病在全球范围内给人类健康造成巨大负担, 但由于缺乏能够真实模拟人体气道结构和功能的体外实验模型, 科学家在研究肺部疾病的发生机制及开发更有效的治疗方法方面仍面临诸多挑战。 这使得构建更具生理相关性的体外气道模型, 成为生物工程与生物医学研究领域亟待解决的问题。 近年来,随着生物制造与生物构建技术的快速发展, 这一目标逐渐成为可能。 在此背景下, 我们基于已有研究提出一种新的理论性模型概念, 称为 “倒置气道-管道模型 (inverted airway-on-a-tube)”。 该模型采用类似管道的结构, 由增强支撑的水凝胶材料构成, 其内部中空部分可用于模拟血管中血流条件下的内皮细胞生长, 外表面则可用于培养气道上皮细胞, 使其在类似真实呼吸环境的气-液界面条件下分化成熟, 并便于进行气溶胶暴露实验。 同时, 该结构还允许加入成纤维细胞等其他间质细胞, 从而更全面地再现真实气道的微环境。 总体而言, 该 “倒置气道-管道模型” 为构建可扩展、 可集成且且更接近人体真实状态的体外气道系统提供了一种新思路, 有望为呼吸系统疾病的基础研究与药物开发带来新的工具和机遇。

  • Open Access

    Utilising multi-modal data-driven network analysis to identify monotherapy and combinational therapy targets in SOX2-dependent squamous cell lung cancer

    by Woochang Hwang, Daniel Kottmann, Wenrui Guo, Méabh MacMahon, Lucia Correia, Sherine Ahmed, Rebecca Harris, Frank McCaughan, Namshik Han

    Drug discovery requires understanding disease mechanisms, making the integration of multi-modal data essential. These data types, including omics, disease-associated, and pathway information, must be combined to uncover therapeutic insights. We developed iPANDDA, a computational pipeline that integrates these data through a network-based approach to predict candidate drug targets for specific diseases. We applied iPANDDA to lung squamous cell carcinoma (LUSC), a subtype of non-small cell lung cancer representing ~25% of global cases. Despite advances in cancer therapeutics, targeted treatments for LUSC remain limited, partly due to a lack of robust models to study carcinogenesis and therapeutic response. The SOX2 gene, amplified in ~50% of patients, plays a critical role in sustaining the cancer phenotype. Using iPANDDA, we identified and validated SOX2-dependent therapeutic targets. In vitro inhibition studies confirmed AKT and mTOR complexes as key monotherapy and combination therapy targets and revealed pathways for SOX2-targeted combination therapies.


  • Open Access

    Utilising multi-modal data-driven network analysis to identify monotherapy and combinational therapy targets in SOX2-dependent squamous cell lung cancer

    by Woochang Hwang, Daniel Kottmann, Wenrui Guo, Méabh MacMahon, Lucia Correia, Rebecca Harris, Frank McCaughan, Namshik Han

    Drug discovery requires a deep understanding of disease mechanisms, making the integration and analysis of diverse, multi-modal data types essential. These data types, spanning omics types, disease- associated, and biological pathway information, often originate from disparate sources and must be combined to uncover critical insights. We have developed iPANDDA ( in-silico Pipeline for Agnostic Network-based Drug Discovery Analysis ), a computational pipeline that integrates multi-modal data through a network-based approach to predict candidate drug target proteins for specific diseases. We applied iPANDDA to lung squamous cell carcinoma (LUSC), a subtype of non-small cell lung cancer (NSCLC) that accounts for approximately 25% of all lung cancer cases globally. Despite advances in cancer therapeutics, targeted therapies specifically approved for LUSC remain lacking, exacerbated by the shortage of robust models for studying LUSC carcinogenesis and therapeutic responses. The SOX2 gene, amplified in about 50% of LUSC patients, plays a critical role in driving and maintaining the cancer phenotype. Using iPANDDA, we identified relevant therapeutic targets for SOX2-dependent LUSC. Selected candidate drug targets were validated in vitro using cell-based models. We conducted target inhibition studies in both SOX2-dependent and non-SOX2-dependent cell lines, evaluating the effects of inhibition and knockout through cell viability assays. Our findings confirmed key monotherapy and combination therapy targets for SOX2-focused models. Specifically, we validated the AKT and mTOR complexes as promising therapeutic targets for LUSC. Additionally, we identified potential pathways for developing novel combination therapies targeting SOX2-dependent LUSC. iPANDDA offers a robust approach to refining and focusing therapeutic strategies for diseases with unmet clinical needs.


  • Open Access

    In vitro platform to model the function of ionocytes in the human airway epithelium

    by Marta Vilà-González, Laetitia Pinte, Ricardo Fradique, Erika Causa, Heleen Kool, Mayuree Rodrat, Carola Maria Morell, Maha Al-Thani, Linsey Porter, Wenrui Guo, et al.

    Background: Pulmonary ionocytes have been identified in the airway epithelium as a small population of ion transporting cells expressing high levels of CFTR (cystic fibrosis transmembrane conductance regulator), the gene mutated in cystic fibrosis. By providing an infinite source of airway epithelial cells (AECs), the use of human induced pluripotent stem cells (hiPSCs) could overcome some challenges of studying ionocytes. However, the production of AEC epithelia containing ionocytes from hiPSCs has proven difficult. Here, we present a platform to produce hiPSC-derived AECs (hiPSC-AECs) including ionocytes and investigate their role in the airway epithelium. Methods: hiPSCs were differentiated into lung progenitors, which were expanded as 3D organoids and matured by air-liquid interface culture as polarised hiPSC-AEC epithelia. Using CRISPR/Cas9 technology, we generated a hiPSCs knockout (KO) for FOXI1, a transcription factor that is essential for ionocyte specification. Differences between FOXI1 KO hiPSC-AECs and their wild-type (WT) isogenic controls were investigated by assessing gene and protein expression, epithelial composition, cilia coverage and motility, pH and transepithelial barrier properties. Results: Mature hiPSC-AEC epithelia contained basal cells, secretory cells, ciliated cells with motile cilia, pulmonary neuroendocrine cells (PNECs) and ionocytes. There was no difference between FOXI1 WT and KO hiPSCs in terms of their capacity to differentiate into airway progenitors. However, FOXI1 KO led to mature hiPSC-AEC epithelia without ionocytes with reduced capacity to produce ciliated cells. Conclusion: Our results suggest that ionocytes could have role beyond transepithelial ion transport by regulating epithelial properties and homeostasis in the airway epithelium.


  • Open Access

    Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters

    by Megan Neary, Joanne Sharp, Eduardo Gallardo-Toledo, Joanne Herriott, Edyta Kijak, Chloe Bramwell, Helen Cox, Lee Tatham, Helen Box, Paul Curley, et al.

    The successful development of a chemoprophylaxis against SARS-CoV-2 could provide a tool for infection prevention that is implementable alongside vaccination programmes. Nafamostat is a serine protease inhibitor that inhibits SARS-CoV-2 entry in vitro, but it has not been characterised for chemoprophylaxis in animal models. Clinically, nafamostat is limited to intravenous delivery and has an extremely short plasma half-life. This study sought to determine whether intranasal dosing of nafamostat at 5 mg/kg twice daily was able to prevent the airborne transmission of SARS-CoV-2 from infected to uninfected Syrian Golden hamsters. SARS-CoV-2 RNA was detectable in the throat swabs of the water-treated control group 4 days after cohabitation with a SARS-CoV-2 inoculated hamster. However, throat swabs from the intranasal nafamostat-treated hamsters remained SARS-CoV-2 RNA negative for the full 4 days of cohabitation. Significantly lower SARS-CoV-2 RNA concentrations were seen in the nasal turbinates of the nafamostat-treated group compared to the control (p = 0.001). A plaque assay quantified a significantly lower concentration of infectious SARS-CoV-2 in the lungs of the nafamostat-treated group compared to the control (p = 0.035). When taken collectively with the pathological changes observed in the lungs and nasal mucosa, these data are strongly supportive of the utility of intranasally delivered nafamostat for the prevention of SARS-CoV-2 infection.


  • Open Access

    Cigarette smoke preferentially induces full length ACE2 expression in differentiated primary human airway cultures but does not alter the efficiency of cellular SARS-CoV-2 infection

    by Linsey M. Porter, Wenrui Guo, Thomas Wm. Crozier, Edward Jd. Greenwood, Brian Ortmann, Daniel Kottmann, James A. Nathan, Ravindra Mahadeva, Paul J. Lehner, Frank McCaughan


  • Open Access

    Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures

    by Wenrui Guo, Linsey M Porter, Thomas Wm Crozier, Matthew Coates, Akhilesh Jha, Mikel McKie, James A Nathan, Paul J Lehner, Edward Jd Greenwood, Frank McCaughan

    Background: There are limited effective prophylactic/early treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral entry requires spike protein binding to the angiotensin-converting enzyme-2 receptor and cleavage by transmembrane serine protease 2 (TMPRSS2), a cell surface serine protease. Targeting of TMPRSS2 by either androgen blockade or direct inhibition is in clinical trials in early SARS-CoV-2 infection. Methods: We used differentiated primary human airway epithelial cells at the air–liquid interface to test the impact of targeting TMPRSS2 on the prevention of SARS-CoV-2 infection. Results: We first modelled the systemic delivery of compounds. Enzalutamide, an oral androgen receptor antagonist, had no impact on SARS-CoV-2 infection. By contrast, camostat mesylate, an orally available serine protease inhibitor, blocked SARS-CoV-2 entry. However, oral camostat is rapidly metabolised in the circulation, with poor airway bioavailability. We therefore modelled local airway administration by applying camostat to the apical surface of differentiated airway cultures. We demonstrated that a brief exposure to topical camostat effectively restricts SARS-CoV-2 infection. Conclusion: These experiments demonstrate a potential therapeutic role for topical camostat for pre- or post-exposure prophylaxis of SARS-CoV-2, which can now be evaluated in a clinical trial.


  • Open Access

    Cigarette smoke preferentially induces full length ACE2 exposure in primary human airway cells but does not alter susceptibility to SARS-CoV-2 infection

    by Linsey M Porter, Wenrui Guo, Thomas Wm Crozier, Edward Jd Greenwood, Brian Ortmann, Daniel Kottmann, James A Nathan, Ravindra Mahadeva, Paul J Lehner, Frank McCaughan

    Cigarette smoking has multiple serious negative health consequences. However, the epidemiological relationship between cigarette smoking and SARS-CoV-2 infection is controversial; and the interaction between cigarette smoking, airway expression of the ACE2 receptor and the susceptibility of airway cells to infection is unclear. We exposed differentiated air-liquid interface cultures derived from primary human airway stem cells to cigarette smoke extract (CSE) and infected them with SARS-CoV-2. We found that CSE increased expression of full-length ACE2 (flACE2) but did not alter the expression of a Type I-interferon sensitive truncated ACE2 that lacks the capacity to bind SARS-CoV-2 or a panel of interferon-sensitive genes. Importantly, exposure to CSE did not increase viral infectivity despite the increase in flACE2. Our data are consistent with epidemiological data suggesting current smokers are not at excess risk of SARS-CoV-2 infection. This does not detract from public health messaging emphasising the excess risk of severe COVID-19 associated with smoking-related cardiopulmonary disease.